Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Feng, Qiang ^a,b,c   Liu, Zhipeng ^a,d   Zhong, Shilong ^e   Li, Ruijun ^f   Xia, Huihua ^a   Jie, Zhuye ^a   Wen, Bo ^a   Chen, Xiaomin ^a   Yan, Wei ^f   Fan, Yanqun ^a   Guo, Zhenyu ^a   Meng, Nan ^a   Chen, Jiyan ^e   Yu, Xiyong ^e   Zhang, Zhiwei ^e   Kristiansen, Karsten ^a,g   Wang, Jun ^a,e,h,i,j   Xu, Xun ^a   He, Kunlun ^f   Li, Guanglei ^a  

^a BGI SHENZHEN   (China)

^b SHANDONG UNIVERSITY   (China)

^c Shenzhen Engineering Laboratory of Detection and Intervention of human intestinal microbiome   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^e GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^f CHINESE PLA GENERAL HOSPITAL   (China)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

ⁱ MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

^j UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; HUMAN; INTESTINE; METABOLOMICS; METAGENOMICS; MICROBIOLOGY; URINE;

CASE-CONTROL STUDIES; CORONARY DISEASE; HUMANS; INTESTINES; METABOLOMICS; METAGENOMICS;

EID: 84959573656     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22525     Document Type: Article

References (40)

1. Graninger, D. J. et al. Metabolomics in coronary heart disease. Heart. Metab 55, 8-12 (2012).
2. Gorenoi, V. et al. CT coronary angiography vs invasive coronary angiography in CHD. GMS Health Technol Assess 8, 1-16 (2012).
3. Khan, M. et al. Contraindications and side effects of commonly used medications in coronary CT angiography. Int. J. Cardiovasc. Imaging 27, 441-449 (2011).
4. Huss, J. M. et al. Nuclear receptor signaling and cardiac energetics. Circ. Res 95, 568-578 (2004).
5. Chilton, R. J. Pathophysiology of coronary heart disease: a brief review. JAOA 104, S5-S8 (2004).
6. Fernandez, C. et al. Plasma lipid composition and risk of developing cardiovascular disease. PLOS ONE 8, e71846 (2013).
7. Zira, A. N. et al. 1H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. J. Proteome. Res 9, 4038-4044 (2010).
8. Griffiths, W. J. et al. Targeted metabolomics for miomarker discovery. Angew. Chem. Int. Ed 49, 5426-5445 (2010).
9. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63 (2011).
10. Koeth, R. A. et al. Intestinal microbiota metabolism of L-carnitione, nutrient in red meat, promotes atherosclerosis. Nat. Med 19, 576-85 (2013).
11. Triba, M. N. et al. PLS/OPLS models in metabolomics: impact of permutation of dataset rows on the K-fold cross-validation quality parameters. Mol. Biosyst 11, 13-19 (2015).
12. Miao, H. et al. Urinary Metabolomics on the biochemical profiles in diet-induced hyperlipidemia rat using ultraperformance liquid chromatography coupled with quadrupole time-of-flight SYNAPT high-definition mass spectrometry. J. Anal. Methods. Chem 2014, ID184162 (2014).
13. Chen, J. et al. Practical approach for the identification and isomer elucidation of biomarkers detected in a metabonomic study for the discovery of individuals at risk for diabetes by integrating the chromatographic and mass spectrometric information. Anal. Chem 80, 1280-1289 (2008).
14. Liu, P. et al. Biomarkers of primary dysmenorrhea and herbal formula intervention: an exploratory metabonomics study of blood plasma and urine. Mol. BioSyst 9, 77-87 (2013).
15. E. Holmes. et al. Gut Microbiota Composition and Activity in Relation to Host Metabolic Phenotype and Disease Risk. Cell Metabolism 15, 559-564 (2012).
16. Carvalheiro, F. et al. Mannitol production by lactic acid bacteria grown in supplemented carob syrup. J. IndMicrobiol. Biotechnol 38, 221-7 (2011).
17. Kets, E. et al. Mannitol, a novel bacterial compatible solute in Pseudomonas putida S12. J Bacteriol 178, 6665-6670 (1996).
18. Zhao, Z. W. et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. Journal of Clinical Oncology 25, 2696-2701 (2007).
19. Olofsson, K. E. et al. Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine production in macrophages. Biochemical and Biophysical Research Communications 370, 348-352 (2008).
20. Matsumoto, T. et al. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr. Med. Chem 14, 3209-3220 (2007).
21. Komatsuzawa, H. et al. The gate controlling cell wall synthesis in Staphylococcus aureus. Mol. Microbiol 53, 1221-1231 (2004).
22. Benowitz, N. L. et al. Sympathomimetic effects of paraxanthine and caffeine in humans. Clin. Pharmacol. Ther 58, 684-691 (1995).
23. Dickinson, H. et al. Creatine supplementation during pregnancy: summary of experimental studies suggesting a treatment to improve fetal and neonatal morbidity and reduce mortality in high-risk human pregnancy. BMC Pregnancy Childbirth 14, 150 (2014).
24. Park, M. T. et al. Phytosphingosine induces apoptotic cell death via caspase8 activation and bax translocation in human cancer cells. Clin. Cancer. Res 9, 878-885 (2003).
25. Santana, P. et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 6, 189-199 (1996).
26. Luan, H. et al. Serum metabolomics reveals lipid metabolism variation between coronary artery disease and congestive heart failure: a pilot study. Biomarkers 18, 314-321 (2013).
27. Dunn, W. B. et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc 6, 1060-1083 (2011).
28. Anderson, M. J. A new method for non-parametric multivariate analysis of variance. Aust. Ecol 26, 32-46 (2001).
29. Xia, J. G. et al. Translational Biomarker Discovery in Clinical Metabolomics: An Introductory Tutorial. Metabolomics 9, 280-299 (2012).
30. Wishart, D. S. et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 35, D521-D526 (2007).
31. Wishart, D. S. et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37, D603-D610 (2009).
32. Wishart, D. S. et al. HMDB 3.0 - The Human Metabolome Database in 2013. Nucleic Acids Res 41, D801-D807 (2013).
33. Ogata, H. et al. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27, 29-34 (1999).
34. Kanehisa, M. et al. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 28, 27-30 (2000).
35. Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60 (2012).
36. Li, R. et al. De novo assembly of human genomes with massively parallel short read sequencing. Genome Research 20, 265-272 (2009).
37. Zhu, W. et al. Ab initio gene identification in metagenomic sequences. Nucleic acids Res 38, e132 (2010).
38. Kent, W. J. BLAT - The BLAST-Like Alignment Tool. Genome Research 12, 656-664 (2002).
39. Altschul, S. F. et al. Basic local alignment search tool. J Mol Biol 215, 403-410 (1990).
40. Sunagawa, S. et al. Metagenomic species profiling using universal phylogenetic marker genes. Nature methods 10, 1196-1199 (2013).